• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

NXP Semiconductors shares rise after UBS upgrade amid strong growth outlook

by October 7, 2024
written by October 7, 2024

Investing.com — Shares of NXP Semiconductors (NASDAQ:NXPI) (F:NXPI) rose on Monday after UBS upgraded the company’s stock to “buy,” from “neutral,” reflecting growing confidence in its long-term growth prospects. 

At 4:43 am (0843 GMT), NXP Semiconductors was trading 1.4% up at €215.

The move comes amid a broader downturn in the semiconductor sector, where NXP has managed to stand out through a combination of inventory management and resilient pricing, setting the stage for a robust recovery in 2025. 

UBS analysts cited several factors for the upgrade, raising their price target to $285, up from the previous target of $275, signaling an optimistic outlook for the stock.

NXP, which has outperformed the analog semiconductor sub-sector this year, has seen its shares lag behind peers, trading at about a 40% discount compared to competitors, down from a 30% discount at the start of the year. 

This disconnect is largely attributed to concerns surrounding its heavy exposure to the automotive industry, which makes up 56% of its revenues. 

The automotive sector has faced significant challenges, leading to fears that companies like NXP, with large auto portfolios, might struggle. However, UBS analysts argue that these fears are exaggerated.

The semiconductor giant is well-positioned to capitalize on the shift toward zonal and domain architectures in vehicles, a transition that is expected to increase the dollar content of microcontroller units per vehicle by more than 30%. 

This shift in electronics architecture will require greater computing capacity in vehicles, and NXP, with its strong portfolio of high-performance MCUs like the S32 family, stands to benefit significantly. 

UBS estimates that NXP’s auto revenues could see high single-digit compounded annual growth over the next few years, even without substantial vehicle production growth. 

The company’s focus on higher-margin, advanced automotive applications such as zonal controllers and domain controllers further strengthens its position in this growing market.

Additionally, UBS flagged NXP’s impressive ability to manage through the semiconductor industry’s recent downcycle. While many of its peers have seen gross margins contract by more than 900 basis points during this period, NXP’s margin contraction was limited to just 50 basis points. 

This is largely due to improvements in operational efficiency, the company’s exit from lower-margin businesses, and strong management of channel inventory and pricing. 

UBS data suggests that NXP has kept its channel inventories healthier than competitors like STMicroelectronics and Infineon (OTC:IFNNY), with pricing declining by only low single digits year-over-year, compared to more significant drops among its peers.

Going forward, UBS anticipates further catalysts that could drive NXP’s stock higher. The upcoming Capital Markets Day in November is expected to feature an upward revision of the company’s gross margin targets, which currently stand at 55% to 58%. 

Analysts believe this revision, along with continued operational improvements, will boost investor confidence and could lead to earnings upgrades for the company.

In terms of valuation, NXP trades at a considerable discount to its U.S. peers, despite its operational strength. UBS views this discount as unwarranted, particularly given the company’s strong positioning for future growth in both automotive and industrial segments. 

The brokerage expects NXP to grow its revenues by 11% in 2025, significantly outpacing close peers, who are forecasted to grow at a rate of 5% to 10%. 

UBS remains confident that NXP’s inventory management and pricing strength will mitigate potential downside risks, setting the stage for a strong recovery as the semiconductor market rebounds. 

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Indonesia stocks higher at close of trade; IDX Composite Index up 0.34%
next post
Too early to call a burst in China property buying a recovery, analysts say

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Dick’s Sporting Goods to buy struggling Foot Locker for $2.4 billion

      May 15, 2025
    • YouTube will stream NFL Week 1 game in Brazil for free

      May 15, 2025
    • 5 new Uber features you should know — including a way to avoid surge pricing

      May 15, 2025
    • American Eagle shares plunge 17% after it withdraws guidance, writes off $75 million in inventory

      May 14, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (462)
    • Stock (6,426)

    Latest News

    • Dick’s Sporting Goods to buy struggling Foot Locker for $2.4 billion
    • YouTube will stream NFL Week 1 game in Brazil for free

    Popular News

    • Energy services sector downgraded at Barclays amid bearish oil macro setting
    • Sana Biotech’s islet cell therapy shows promise in diabetes; shares surge 150% postmarket

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy